AG
ENTA icon

Aperio Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Aperio Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$984K Buy
23,375
+6,808
+41% +$300K ﹤0.01% 1596
2020
Q3 		$758K Buy
16,567
+4,782
+41% +$232K ﹤0.01% 1586
2020
Q2 		$592K Buy
11,785
+3,364
+40% +$174K ﹤0.01% 1692
2020
Q1 		$433K Buy
8,421
+821
+11% +$43.8K ﹤0.01% 1725
2019
Q4 		$470K Sell
7,600
-325
-4% -$20.1K ﹤0.01% 1834
2019
Q3 		$476K Sell
7,925
-111
-1% -$8.24K ﹤0.01% 1781
2019
Q2 		$678K Buy
8,036
+406
+5% +$36.5K ﹤0.01% 1614
2019
Q1 		$729K Sell
7,630
-23
-0.3% -$2.06K ﹤0.01% 1532
2018
Q4 		$542K Buy
7,653
+359
+5% +$27.5K ﹤0.01% 1631
2018
Q3 		$623K Sell
7,294
-83
-1% -$8.31K ﹤0.01% 1655
2018
Q2 		$855K Buy
7,377
+89
+1% +$8.88K ﹤0.01% 1482
2018
Q1 		$590K Buy
7,288
+899
+14% +$69.2K ﹤0.01% 1611
2017
Q4 		$375K Buy
6,389
+302
+5% +$15.1K ﹤0.01% 1841
2017
Q3 		$285K Buy
6,087
+356
+6% +$14.3K ﹤0.01% 1946
2017
Q2 		$206K Buy
+5,731
New +$183K ﹤0.01% 2084

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aperio Group's ENTA Position: Q4 2020 in Review

Aperio Group increased its Enanta Pharmaceuticals (ENTA) stake by 41% in Q4 2020, buying an estimated $300K and bringing the position to 23,375 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #1596.

Aperio Group first reported a position in ENTA in Q2 2017 and has held it in 15 quarters since. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Aperio Group held 23,375 shares of Enanta Pharmaceuticals worth $984K as of Q4 2020.
  • Aperio Group bought 6,808 Enanta Pharmaceuticals shares in Q4 2020, an estimated $300K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1596 holding.
  • Aperio Group first reported a position in Enanta Pharmaceuticals in Q2 2017 and has held it in 15 quarters since.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.